Sana Biotechnology, Inc. announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana's proprietary HIP-modified (HIP) technology were presented at the 65thAmerican Society of Hematology (ASH) Annual Meeting in San Diego, CA. Sana?s hypoimmune platform is designed to create cells ex vivo that can evade the patient?s immune system to enable the transplant of allogeneic cells without the need for immunosuppression. are applying the hypoimmune technology to both donor-derived allogeneic T cells, with the goal of making potent and persistent CAR T cells at scale, and pluripotent stem cells, which can then be differentiated into multiple cell types at scale.

Preclinical data published in peer-reviewed journals demonstrate across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arms of the immune system while retaining their activity. most advanced programs utilizing this platform include an allogeneic CAR T program targeting CD19+ cancers, an allogeneic CAR T program for B-cell mediated autoimmune diseases, an allogeneic CAR T program targeting CD22+ cancers, and stem-cell derived pancreatic islet cells for patients with type 1 diabetes.